Glint Pharmaceuticals Receives FDA IND Acceptance for Clinical Study for Phase 1/2 Clinical Trial of Antibiotic Drug-Releasing Contact Lens, ACL5
UF startup Glint Pharmaceuticals (Glint), a clinical-stage biotechnology company focused on developing a next-generation contact lens drug delivery technology, announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate its antibiotic drug delivery contact lens, ACL5. Glint anticipates beginning the investigation in Q2 2023.
Glint Pharmaceuticals Begins Clinical Trials to Treat Corneal Abrasions and Infections
UF startup Glint Pharmaceuticals, an ophthalmic pharmaceutical company that delivers medicated contact lenses to treat eye diseases, announces the start of a phase I safety study to treat corneal infections and superficial injuries.
Glint Pharmaceuticals Announces Formation of Clinical Advisory Board
UF startup Glint Pharmaceuticals, an ophthalmic pharmaceutical company that delivers medicated contact lenses to treat eye diseases, announces the formation of a clinical advisory board composed of notable and experienced clinicians in ophthalmology and optometry.
Glint Pharmaceuticals to Begin Clinical Testing on Contact Lens to Prevent COVID-19 Virus Infection
UF startup Glint Pharmaceuticals, an ophthalmic pharmaceutical company that delivers medicated contact lenses to treat eye diseases, has developed a patented technology for delivery of an anti-COVID-19 formulation to the ocular surface to prevent and treat infections. The proprietary formulation combines a well-tolerated ocular chemistry with the Glint drug delivery contact lens to kill a […]